[{"orgOrder":0,"company":"Forty Seven","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Magrolimab","moa":"CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Forty Seven","amount2":4.9000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.9000000000000004,"dosageForm":"","sponsorNew":"Forty Seven \/ Gilead ","highestDevelopmentStatusID":"8","companyTruncated":"Forty Seven \/ Gilead "}]

Find Clinical Drug Pipeline Developments & Deals by Forty Seven

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Gilead gains Forty Seven’s investigational immuno-oncology therapy in multiple clinical studies, supporting its strategic focus in oncology as well as innovative pipeline.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : $4,900.0 million

                          March 02, 2020

                          Lead Product(s) : Magrolimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Gilead Sciences

                          Deal Size : $4,900.0 million

                          Deal Type : Acquisition

                          blank